| An overview of artificial intelligence in oncology E Farina, JJ Nabhen, MI Dacoregio, F Batalini, FY Moraes Future science OA 8 (4), FSO787, 2022 | 89 | 2022 |
| Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs … F Batalini, EG Peacock, L Stobie, A Robertson, J Garber, JN Weitzel, ... Breast Cancer Research 21, 1-10, 2019 | 77 | 2019 |
| Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer F Batalini, N Xiong, N Tayob, M Polak, J Eismann, LC Cantley, GI Shapiro, ... Clinical Cancer Research 28 (8), 1493-1499, 2022 | 44 | 2022 |
| Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib F Batalini, SL Moulder, EP Winer, HS Rugo, NU Lin, GM Wulf JCO Precision Oncology 4, 2020 | 44 | 2020 |
| Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias C Corti, M Cobanaj, F Marian, EC Dee, MR Lloyd, S Marcu, ... Cancer Treatment Reviews 108, 102410, 2022 | 43 | 2022 |
| Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin Case report and review of the literature CR Petri, R Patell, F Batalini, D Rangachari, RW Hallowell Respiratory Medicine Case Reports, 100834, 2019 | 43 | 2019 |
| High-dose melphalan and stem cell transplantation in patients on dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease F Batalini, L Econimo, K Quillen, JM Sloan, S Sarosiek, D Brauneis, ... Biology of Blood and Marrow Transplantation 24 (1), 127-132, 2018 | 41 | 2018 |
| Germline genetic testing in breast cancer: rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years NV Desai, S Yadav, F Batalini, FJ Couch, NM Tung Cancer 127 (6), 828-833, 2021 | 35 | 2021 |
| Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers F Batalini, DC Gulhan, V Mao, A Tran, M Polak, N Xiong, N Tayob, ... Clinical Cancer Research 28 (21), 4714-4723, 2022 | 30 | 2022 |
| PARP-inhibition reprograms macrophages toward an anti-tumor phenotype L Wang, D Wang, O Sonzogni, S Ke, Q Wang, A Thavamani, F Batalini, ... Cell reports 41 (2), 2022 | 30 | 2022 |
| Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches F Raheem, SA Karikalan, F Batalini, A El Masry, L Mina International Journal of Molecular Sciences 24 (22), 16198, 2023 | 27 | 2023 |
| PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond MCS Menezes, F Raheem, L Mina, B Ernst, F Batalini Cancers 14 (17), 4332, 2022 | 27 | 2022 |
| Cancer complaints: The profile of patients from the emergency department of a Brazilian oncology teaching hospital F Batalini, M Gomes, I Fábio, F Kuwae, G Macanhan, JLB Pereira F1000Research 6, 2017 | 15 | 2017 |
| Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: a systematic review and meta-analysis ACM Comini, BM Carvalho, MJB Moreira, PCA Reis, L Colapietro, ... Clinical Breast Cancer, 2023 | 9 | 2023 |
| Exposing Vulnerabilities in Clinical LLMs Through Data Poisoning Attacks: Case Study in Breast Cancer A Das, A Tariq, F Batalini, B Dhara, I Banerjee medRxiv, 2024 | 7 | 2024 |
| Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline … F Batalini, RW Madison, ES Sokol, DX Jin, KT Chen, B Decker, ... JCO Precision Oncology 7, e2300091, 2023 | 7 | 2023 |
| Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR … F Batalini, R Madison, DC Pavlick, E Sokol, T Snow, A Sondhi, ... Journal of Clinical Oncology 39 (15_suppl), 10512-10512, 2021 | 6 | 2021 |
| Overcoming barriers to resident scholarly productivity and research at a large academic institution M Dennis, F Batalini, L Demers, A Upadhyay MedEdPublish 8, 2019 | 6 | 2019 |
| Prospective study of supplemental screening with contrast-enhanced mammography in women with elevated risk of breast cancer: results of the prevalence round BK Patel, MB Carnahan, D Northfelt, K Anderson, GL Mazza, VJ Pizzitola, ... Journal of Clinical Oncology 42 (32), 3826-3836, 2024 | 5 | 2024 |
| Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry S Ke, F Dang, L Wang, JY Chen, MT Naik, W Li, A Thavamani, N Kim, ... Nature Communications 15 (1), 3220, 2024 | 5 | 2024 |
Gerburg WulfAssociate Professor in Medicine, Harvard Medical SchoolE-mail megerősítve itt: bidmc.harvard.edu
